Retifanlimab Market Summary
Key Factors Driving Retifanlimab Growth
1. Expanding Regulatory Approvals Across Oncology Indications
Retifanlimab’s commercial growth is strongly supported by expanding regulatory approvals.
• In 2023, the U.S. FDA approved retifanlimab for metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) based on results from the POD1UM-201 study.
• In May 2025, the FDA approved retifanlimab in combination with carboplatin and paclitaxel for advanced squamous cell carcinoma of the anal canal (SCAC) and also as a monotherapy option.
• Japan approved the drug in 2025 for first-line treatment of advanced anal cancer, expanding its geographic footprint.
These approvals expand the treatable population and create new revenue streams across multiple oncology markets.
2. Strong Clinical Efficacy in Late-Stage Trials
Robust clinical trial data are driving physician confidence and adoption.
Key clinical results:
• In the POD1UM-303/InterAACT 2 Phase III trial, adding retifanlimab to chemotherapy reduced the risk of disease progression or death by 37% compared with chemotherapy alone.
• Median progression-free survival improved to 9.3 months vs 7.4 months with placebo combination therapy.
Earlier studies in MCC also showed strong responses:
• Objective response rate (ORR) of 52% in treatment-naïve metastatic MCC patients.
• Many responses were durable, with 62% lasting at least 12 months.
These efficacy outcomes position retifanlimab as a competitive PD-1 therapy in rare cancers.
3. Growing Market Opportunity in Rare and Hard-to-Treat Cancers
Retifanlimab addresses cancers with limited treatment options, creating strong demand.
Merkel Cell Carcinoma
• MCC is a rare but aggressive skin cancer with a 5-year survival rate of ~14% for metastatic disease.
• Incidence is rising globally, particularly in older adults.
Anal Cancer
• Anal cancer incidence has been increasing worldwide due to factors such as HPV infection prevalence and improved screening.
Because both cancers historically lacked effective targeted therapies, immune checkpoint inhibitors like retifanlimab are rapidly becoming standard treatment.
4. Expansion Within the Immuno-Oncology Market
Checkpoint inhibitors targeting the PD-1/PD-L1 pathway represent one of the fastest-growing oncology drug classes.
Advantages supporting retifanlimab adoption:
• Proven mechanism validated by blockbuster drugs like nivolumab and pembrolizumab.
• Potential use in combination regimens with chemotherapy or targeted therapies.
• Ongoing clinical trials exploring additional tumor types.
This broader immuno-oncology ecosystem supports continued demand for PD-1 inhibitors.
5. Increasing Commercial Contribution to Incyte’s Oncology Portfolio
Retifanlimab is part of Incyte’s strategy to diversify revenue beyond its flagship drug Jakafi.
Commercial performance indicators:
• Early launch sales for Zynyz were approximately $34.6 million during the first nine months of 2025, compared with $1.8 million the prior year, reflecting rapid uptake after approval.
• Continued approvals and expanded labeling are expected to accelerate adoption across oncology centers.
Retifanlimab Recent Developments
• In January 2026, Incyte announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending the approval of Zynyz (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC).
“Retifanlimab Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Retifanlimab for approved indication like Merkel cell carcinoma, Squamous cell cancer; as well as potential indications like Breast cancer; Endometrial cancer; Non-small cell lung cancer, Glioblastoma, Glioma, Head and neck cancer, and Liposarcoma in the 7MM. A detailed picture of Retifanlimab’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Retifanlimab for approved and potential indications. The Retifanlimab market report provides insights about Retifanlimab’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Retifanlimab performance, future market assessments inclusive of the Retifanlimab market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Retifanlimab sales forecasts, along with factors driving its market.
Retifanlimab Drug Summary
Retifanlimab is a humanized programmed death receptor-1 (PD-1) blocking monoclonal antibody developed by Incyte, administered via intravenous infusion every 4 weeks (500 mg dose), indicated for adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) under accelerated approval based on tumor response rate and duration; and for squamous cell carcinoma of the anal canal (SCAC), either in combination with carboplatin and paclitaxel as first-line therapy for inoperable locally recurrent or metastatic disease, or as monotherapy for locally recurrent or metastatic SCAC after progression on or intolerance to platinum-based chemotherapy. By binding to PD-1 on T-cells, it prevents interaction with PD-L1/PD-L2, thereby potentiating T-cell activity and enhancing anti-tumor immune response against cancer cells. It carries warnings for immune-mediated adverse reactions across organ systems including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, dermatologic events, myocarditis, and neurological toxicities, requiring monitoring, withholding, or discontinuation based on severity. The report provides Retifanlimab’s sales, growth barriers and drivers, post usage and approvals in multiple indications.
Scope of the Retifanlimab Market Report
The report provides insights into:
• A comprehensive product overview including the Retifanlimab MoA, description, dosage and administration, research and development activities in approved indications like Merkel cell carcinoma, Squamous cell cancer; as well as potential indications like Breast cancer; Endometrial cancer; Non-small cell lung cancer, Glioblastoma, Glioma, Head and neck cancer, and Liposarcoma.
• Elaborated details on Retifanlimab regulatory milestones and other development activities have been provided in Retifanlimab market report.
• The report also highlights Retifanlimab‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The Retifanlimab market report also covers the patents information, generic entry and impact on cost cut.
• The Retifanlimab market report contains current and forecasted Retifanlimab sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Retifanlimab market report also features the SWOT analysis with analyst views for Retifanlimab in approved and potential indications.
Methodology
The Retifanlimab market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Retifanlimab Analytical Perspective by DelveInsight
• In-depth Retifanlimab Market Assessment
This Retifanlimab sales market forecast report provides a detailed market assessment of Retifanlimab for approved indication like Merkel cell carcinoma, Squamous cell cancer; as well as potential indications like Breast cancer; Endometrial cancer; Non-small cell lung cancer, Glioblastoma, Glioma, Head and neck cancer, and Liposarcoma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Retifanlimab sales data uptil 2034.
• Retifanlimab Clinical Assessment
The Retifanlimab market report provides the clinical trials information of Retifanlimab for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.
Retifanlimab Competitive Landscape
The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.
Retifanlimab Market Potential & Revenue Forecast
• Projected market size for the Retifanlimab and its key indications
• Estimated Retifanlimab sales potential (Retifanlimab peak sales forecasts)
• Retifanlimab Pricing strategies and reimbursement landscape
Retifanlimab Competitive Intelligence
• Number of competing drugs in development (pipeline analysis)
• Retifanlimab Market positioning compared to existing treatments
• Retifanlimab Strengths & weaknesses relative to competitors
Retifanlimab Regulatory & Commercial Milestones
• Retifanlimab Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity
Retifanlimab Clinical Differentiation
• Retifanlimab Efficacy & safety advantages over existing drugs
• Retifanlimab Unique selling points
Retifanlimab Market Report Highlights
• In the coming years, the Retifanlimab market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Retifanlimab companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Retifanlimab’s dominance.
• Other emerging products for Merkel cell carcinoma, Squamous cell cancer; as well as potential indications like Breast cancer; Endometrial cancer; Non-small cell lung cancer, Glioblastoma, Glioma, Head and neck cancer, and Liposarcoma are expected to give tough market competition to Retifanlimab and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Retifanlimab in approved and potential indications.
• Analyse Retifanlimab cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Retifanlimab sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Retifanlimab in approved and potential indications.
Key Questions
• What is the class of therapy, route of administration and mechanism of action of Retifanlimab? How strong is Retifanlimab’s clinical and commercial performance?
• What is Retifanlimab’s clinical trial status in each individual indications such as Merkel cell carcinoma, Squamous cell cancer; as well as potential indications like Breast cancer; Endometrial cancer; Non-small cell lung cancer, Glioblastoma, Glioma, Head and neck cancer, and Liposarcoma and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Retifanlimab Manufacturers?
• What are the key designations that have been granted to Retifanlimab for approved and potential indications? How are they going to impact Retifanlimab’s penetration in various geographies?
• What is the current and forecasted Retifanlimab market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Retifanlimab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Retifanlimab for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is Retifanlimab? What is the duration of therapy and what are the geographical variations in cost per patient?
